首页>投融资
Vedanta Biosciences
未公开
Vedanta Biosciences Inc is a spin-off from Yale University, a subsidiary of PureTech Health, a biotechnology company pioneering the development of defined bacterial consortia as oral therapies that modulate the human microbiome to treat disease.In January 2021, Pfizer Inc invested $25 million in Vedanta Biosciences Inc.In July 2021, Vedanta Biosciences closed of a $68 million Series D financing.In January 2021, Pfizer Invested $25 million in Vedanta Biosciences which focused on developing a new category of therapies for immune-mediated diseases based on rationally defined consortia of human microbiome-derived bacteria.In June 2020, the company raised an additional $12 million series C/C-2 financing round, bringing the total capital to $71.1 million.In September 2019, the company raised a $16.6 million series C-2 financing round, bringing the total capital raised in its series C and C-2 round to $62.1 million.In May 2018, the company raised an additional $18
基本信息
-
公司全称Vedanta Biosciences Inc
-
类型免疫疗法开发商
-
产业领域药品研发/制造
-
公司人数51~100人
-
地址19 BLACKSTONE STREET,THIRD FLOOR CAMBRIDGE MASSACHUSETTS 02139; US; Telephone: +18577061427;
-
联系电话(857)706-1427
-
邮箱info@vedantabio.com
-
成立时间2010-01-01
投融资
-
2023-04-25未公开1.065亿美元Bill and Melinda Gates FoundationAXA IM AltsSeventure PartnersQUAD辉瑞Revelation PartnersAtlantic NeptuneReimagined VenturesPEAK6Hambro PerksK2 HealthVenturesSkyviews Life ScienceAMR Action FundKorea Investment PartnersKorea Investment＆SecuritiesPureTech Health
-
2021-07-21D轮6800万美元JSR CorporationHealth for Life Capital fundMagnetar CapitalVerition Fund ManagementSymbiosisSkyviews Life ScienceShumway CapitalRock Springs Capital
-
2021-01-21未公开2500万美元Pfizer Breakthrough Growth Initiative
-
2020-09-30未公开7690万美元Biomedical Advanced Research and Development Authority
-
2019-12-05捐赠/众筹/授予580万美元CARB-X
-
2019-09-23C+轮1660万美元QUAD易凯资本Partners InvestmentSV InvestmentSymbiosisFC CapitalShinhan Capital
-
2019-05-13C轮(C2)4550万美元Shumway CapitalJSR CorporationPartners Investment
-
2018-12-25C轮(C1)2700万美元Bill and Melinda Gates FoundationSeventure Partners百时美施贵宝InvescoRock Springs CapitalPureTech Health
-
2018-07-10捐赠/众筹/授予未透露Crohn's & Colitis Foundation
-
2017-11-03捐赠/众筹/授予540万美元CARB-X
-
2016-06-06PE5000万美元Rock Springs CapitalInvescoPureTech Health
- 加载更多
相关投融资企业
PreA轮
Epitopea Ltd develops cancer immunotherapies intended to offer therapeutics targeting a novel class of tumour-specific antigen. The company's technology platform builds on our proprietary and innovative approach to identifying shared, aberrantly expressed tumour-specific antigens (aeTSA), known as CryptigenTM TSAs, curing cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication.In May 2022, Novateur Ventures had participated in the $13.6M (£10.3M) seed investment raised by Epitopea Ltd.In April 2022, Epitopea had announced a $13.6M seed investment from Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital and Fonds de solidarité FTQ
C轮
Alpha-9 Oncology 是一家处于临床阶段的放射性药物公司，致力于开发差异化和高度靶向性的放射性药物，有望显著改善癌症患者的治疗。Alpha-9 运用专有技术和深厚的基础专业知识，走在定制放射性药物工程的前沿，这些药物经过优化，可选择性地向肿瘤部位输送射线，同时最大限度地减少脱靶效应。Alpha-9 正在推进一个强大的新型放射性药物管线，该管线采用系统化的分子设计方法，具有向多个有效肿瘤靶点扩展的广泛潜力。
A轮
March Biosciences是一家临床阶段生物技术公司。该公司致力于治疗对现有免疫疗法无反应的挑战性癌症。其主要资产MB-105是一种以CD5为靶点的嵌合抗原受体T细胞（“CAR-T”）疗法，CD5是一个在正常和恶性T细胞（包括T细胞相关的白血病和淋巴瘤）中广泛表达的蛋白质。这限制了其作为癌症治疗靶点的用途，因为正常免疫系统功能所需的健康T细胞将与恶性T细胞一起被破坏。MB-105经过特别设计，既能保留健康的T细胞，又能保持对CD5阳性肿瘤细胞的杀伤力。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息